Incyte | INCY - Loan Capital


Incyte reported $29.41M in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agenus USD 169.66M 146.06M Dec/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 2.48B 931K Mar/2026
Amgen USD 51.89B 1.88B Mar/2026
BioCryst Pharmaceuticals USD 395.2M 33.48M Mar/2026
Biogen USD 6.29B 1.7M Mar/2026
BioMarin Pharmaceutical USD 1.43B 833.11M Mar/2026
Bristol-Myers Squibb USD 42.15B 698M Mar/2026
Eli Lilly USD 39.37B 1.5B Mar/2026
Gilead Sciences USD 20.86B 1.27B Mar/2026
Incyte USD 29.41M 785K Mar/2026
Ionis Pharmaceuticals USD 1.91B 9M Mar/2026
MacroGenics USD 70M 256K Dec/2025
Merck USD 46.67B 77M Mar/2026
Moderna USD 603M 7M Mar/2026
Nektar Therapeutics USD 63.16M 44.35M Dec/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 37.45B 7.86B Mar/2026
Novartis USD 29.59B 5.35B Dec/2025
Pfizer USD 60.57B 1.08B Mar/2026
PTC Therapeutics USD 286.94M 1.74B Mar/2026
Puma Biotechnology USD 10.87M 222K Jun/2025
Regeneron Pharmaceuticals USD 1.99B 719.7M Mar/2026
Sarepta Therapeutics USD 838.16M 9.19M Mar/2026
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025